Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol–Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database

IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C)–lowering therapies are a cornerstone of prevention in atherosclerotic cardiovascular disease. With the introduction of generic formulations and the release of new therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Cardiol
Auteurs principaux: Sumarsono, Andrew, Lalani, Hussain S., Vaduganathan, Muthiah, Navar, Ann Marie, Fonarow, Gregg C., Das, Sandeep R., Pandey, Ambarish
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2020
Sujets:
Brief Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489407/
https://ncbi.nlm.nih.gov/pubmed/32902560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.3723
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires